What are your top takeaways from ASN Kidney Week 2025?  

Atacicept (ORIGIN Phase 3 Trial)Result: At 36 weeks, atacicept achieved a 46% reduction in proteinuria from baseline and 42% vs placebo (p<0.0001). Safety profile was favorable, with fewer serious adverse events than placebo. First large-scale evidence that dual BAFF/APRIL inhibition can m...